page 1 of 6
Agenda for the 20th meeting of the European Network for
Diagnostics of "Imported" Viral Diseases (ENIVD) and
3rd meeting of the ENIVD-CLRN on Thursday 12th - Saturday 14th May 2011
at the Club Hotel Sera Antalya, Turkey
DRAFT 06.05.11
All Meetings will take place in the “Club Building” for rooms
please see tables below
(Please also check the directing boards in the hotel in case of changes)
Thursday 12th of May Morning
Time 09:00-13:00 h O9:00-13:00h
Room Workshop Room 6 Workshop Room 7
Meeting IFA-Workshop Meeting of the Steering Committee
Thursday 12th of May Afternoon
Time 14:00-18:15 h 14:00-18:00h
Room Phaselis Hall Workshop Room 8
Meeting ENIVD Working-Group Meeting Meeting of the EUPHEM
Friday 13th of May and Saturday 14th of May
Time FRI 09:00-18:00h SAT 09:15-12:15
Room Phaselis Hall Phaselis Hall
Meeting ENIVD/ENIVD-CLRN Meeting ENIVD/ENIVD-CLRN Meeting
page 2 of 6
Thursday the 12th of May
09:00 IFA Workshop (EUROIMMUN)
14:00 Welcome (M. Niedrig)
Working group meeting for Hantaviruses (Chair: P. Heyman/A. Vaheri)
14:05 New markers for severe course of Puumala virus infection: complement activation, 90k/Mac2bp and pentraxin-3 (A. Vaheri)
14:20 Current situation on hantavirus infection in Turkey (Y. Uyar)
14:35 Hantavirus outbreak in Germany in 2010: the year thereafter (R. Ulrich)
14:50 Hantavirus infection in three family members returning from Cuba (F. Rovida)
15:05 Presentation and update on recent investigations (S. Eßbauer)
15:20 Re-emergence of hantavirus and differential diagnosis of hemorrhagic fever in Albania (M. Kota)
15:35 Emergence of a novel variant of Dobrava-Belgrade hantavirus causing fatal cases of hemorrhagic fever with renal syndrome in Eastern Europe (B. Klempa)
15:50 Coffee break
Working group meeting for Phleboviruses (Chair: N.N.)
16:20 A novel phlebovirus in sandflies collected in Lefkas Island, Greece (A. Papa)
16:35 Review of sandfly fever virus infections in Turkey for last 3 years (D. Yağçi Çağlayik)
Working group meeting for TBE virus (Chair: M. Niedrig)
16:50 Characterisation of TBEV field isolates from Switzerland (C. Beuret)
17:05 Exchanging of TBEV subtypes between tick species in Estonia, Latvia and Eastern Poland (I. Golovljova)
17:20 Recent investigations on the phylogeny and biological properties of TBEV (S. Eßbauer)
17:35 Relation of genetic phylogeny and geographical distance of tick-borne encephalitis virus in Central Europe ( M. Weidmann)
Working group meeting for West Nile virus (Chair: M. Niedrig)
page 3 of 6
17:50 Outbreak of West Nile infections in Greece (A. Papa)
18:05 End of Session
In parallel to the ENIVD working group meetings there will be the EUPHEM Meeting 2011 from 14.00 – 17.00 hrs. See separate agenda.
page 4 of 6
Friday the 13th of May
ECDC / ENIVD-CLRN issues (Chair: M. Niedrig)
09:00 Welcome by the hosting Refik Saydam National Public Health Agency (Gülay Korukluoğlu)
09:10 Welcome and introduction of new members/deputies: Ivan-Christian Kurolt (Croatia); Sebastien Plumet (France); Rolf Horstmann (Germany); Concetta Castilletti, Elisa Franchin, Francesca Rovida (Italy); Chantal Reusken (Netherlands); Miguel Martinez (Spain) new partners and guests: Norbert Nowotny (Austria); Birgit Arnold, Erik Lattwein, Thomas Laue (Germany); Mateja Jelovšek (Slovenia); Handan Kalaycıoğlu, Dilek Yağçi Çağlayik, Sultan Yolbakan (Turkey) Fellows: Giovana Jaramillo Gutierrez (RIVM); Katherina Zakikhany (HPA)
09:30 WP 1: Management of the ENIVD-CLRN (M. Niedrig)
09:45 WP 1: Administrational issues (B. Arnold)
10:00 WP 2: Epidemic Intelligence activities (A. Tenorio)
10:15 WP 3: Support activities (P. Dubois)
10:30 WP 4: Preparedness activities (O. Donoso Mantke)
10 :45 Coffee break
11:15 WP 5: Training activities (M. Koopmans)
11:30 WP 5: Training activities (C. Escadafal, RKI)
11:45 WP 5: Training activities (J. Vanhomwegen, Insitut Pasteur)
12:00 WP5 : Training activities (K. Zakikhany, HPA)
12:15 WP 5: Training activities (G. Jaramillo, RIVM)
12:30 New ECDC perspectives (H. Zeller)
12:45 EuroWestNile: a research project funded by the 7th Framework Programme (A. Tenorio)
page 5 of 6
13:00 Presentation of EpiSouth (H. Kalaycıoğlu)
13:15 Lunch break (group picture in front of Hotel)
Surveillance (Chair: M. Niedrig)
15:15 Emergence of West Nile Virus infections in humans in Turkey (G. Korukluoğlu)
15:30 The German Arbovirus Surveillance and Mosquito Monitoring Program 2009-10 (J. Schmidt-Chanasit/ R. Horstmann)
15:45 Monitoring of arboviruses in Ticino – preliminary results (O. Engler)
16:00 Surveillance of WNV disease, dengue and chikungunya fever in Veneto Region, Italy 2010 (L. Barzon)
16:15 Coffee break
16:45 Overview on the West Nile situation in Europe (N. Nowotny)
17:00 Dengue virus emergence in metropolitan France, 2010 (M. Grandadam)
17:15 Increase of dengue cases in 2010 (M. Van Esbroeck)
17:30 The ENIVD-CLRN hanta survey 2010 (P. Heyman)
17:45 Multiple co-infections of rodents with hantaviruses, leptospira and babesia in Croatia (I-C. Kurolt)
18:00 End of Session
19:30 Dinner
page 6 of 6
Saturday the 14th of May
Diagnostic and Research reports (Chair: O. Donoso Mantke)
09:15 3 new assays for CCHF-, Dengue- and Chikungunya virus. (T. Laue)
09:30 Alkhurma hemorrhagic fever virus infection in an Italian traveller returning from Egypt (C Castilletti)
09:45 Short overview of the Hospital Clinic Microbiology Department, current and future plans on arboviruses (M. Martinez)
10:00 New diagnostic tools for CCHFV (A. Mirazimi)
10:15 Coffee break
Outbreak reports (Chair: M. Koopmans)
10:45 Viral features associated to chikungunya virus emergence in metropolitan France ( I. Leparc-Goffart)
11:00 Suspected Lassa case in Sweden (A. Mirazimi)
11:15 The genetic and phylogenetic identification of the first Croatian autochtonuos Dengue virus infection (I-C. Kurolt)
11:30 Imported cases of dengue virus infection in Emilia-Romagna,Italy, 2010 (V. Sambri)
Miscellaneous (Chair: M. Niedrig)
11:45 Future tasks; next meetings
12:00 End of ENIVD/ENIVD-CLRN meeting
12:15 Lunch
13:00 Sight-Seeing
ENIVD-meetingParticipants
Antalya as of 06.05.2011
n° name county bez
1 Dr. Aberle, Stephan Austria2 Dr. Alves, Maria Joao Portugal3 Dr. Avšič-Županc, Tatjana Slovenia4 Arnold Birgit Germany5 Dr. Barzon, Luisa Italy6 Dr. Beuret, Christian Switzerland7 Dr. Brown, David UK8 Dr. Castiletti, Concetta Italy9 Dr. Chinikar, Sadegh Iran
10 Dr. Christova, Iva Bulgaria11 Dr. Di Caro, Antonino Italy12 Dr. Donoso Mantke, Oliver Germany
13 Dr. Dubois, Philippe France
14 Dr. Duffy, Margaret Ireland
15 Dr. Engler, Olivier Switzerland
16 Escadafal, Camille Fellow
17 Dr. Eßbauer, Sandra Germany
18 Dr. Fomsgaard, Anders Denmark19 Dr. Franchin, Elisa Italy20 Dr. Garcia Costa, Juan Spain
21 Dr. Gjeruldsen-Dudman, Susanne Norway
22 Dr. Golovljova, Irina Estonia
23 Dr. Grandadam, Marc France
24 Dr. Hewson, Roger UK
25 Heyman, Paul Belgium
26 Prof. Horstmann, Rolf Germany
27 Dr. Hukic, Mirsada Bosnia- Herz.
28 Jelovšek, Mateja Slovenia29 Jaramillo Gutierrez, Giovanna Fellow30 Dr. Kalaycıoğlu, Handan Turkey31 Dr. Kis, Zoltan Hungary32 Dr. Klempa, Boris Slovakia33 Dr. Kolupaeva, Tatjana Latvia
34 Dr. Koopmanns, Marion Netherlands
35 Dr. Korukluoglu, Gulay Turkey
36 Dr. Kota, Majlinda Albania
37 Kurolt, Ivan-Christian Croatia
38 Dr. Lattwein, Erik EUROIMMUN
39 Dr. Laue, Thomas Germany
40 Dr. Leparc-Goffart, Isabelle France
41 Dr. Lipnickiene, Vilnele Lithuania
42 Litzba, Nadine Germany
43 Dr. Manuguerra, Jean-Claude France
44 Dr. Martina, Byron Netherlands
45 Dr. Martinez, Miguel Spain
46 Dr. Mirazimi, Ali Sweden
47 Dr. Niedrig, Matthias Germany
ENIVD-meetingParticipants
Antalya as of 06.05.2011
48 Dr. Opp, Matthias Luxembourg
49 Dr. Pannetier, Delphine France
50 Dr. Papa, Anna Greece
51 Dr. Plumet, Sebastien France
52 Dr. Reusken, Chantal Netherlands
53 Dr. Rovida, Francesca Italy
54 Dr. Sambri, Vittorio Italy
55 Dr. Schädler, Regina Germany
56 Dr. Schmitdt-Chanasit, Jonas Germany
57 Dr, Schutten, Martin Netherlands
58 Dr. Storozenko, Jelena Latvia59 Dr. Tenorio, Antonio Spain60 Dr. Tordo, Noel France
61 Dr. Ulrich, Rainer Germany
62 Dr. Uyar, Yavuz Turkey
63 Dr. Vaheri, Antti Finland
64 Dr. Van Esbroeck, Marjan Belgium
65 Vanhomwegen, Jessica Fellow
66 Dr. Weidman, Manfred Germany67 Dr. Yagci Caglayik, Dilek Turkey68 Dr. Yolbakan, Sultan Turkey69 Dr. Zakikhany, Katherina Fellow70 Dr. Zelená, Hana Czech Rep.71 Dr. Zeller, Hervé ECDC
ENIVD-meetingParticipants IFAworkshop
Antalya as of 06.05.2011
n° name county1 Dr. Aberle, Stephan Austria2 Dr. Barzon, Luisa Italy3 Dr. Chinikar, Sadegh Iran4 Dr. Christova, Iva Bulgaria5 Dr. Engler, Olivier Switzerland6 Dr. Gjeruldsen-Dudman, Susanne Norway7 Dr. Golovljova, Irina Estonia8 Jaramillo Gutierrez, Giovanna Fellow9 Jelovšek, Mateja Slovenia
10 Dr. Leparc-Goffart, Isabelle France11 Dr. Lipnickiene, Vilnele Lithuania12 Dr. Pannetier, Delphine France13 Dr. Rovinda, Francesca Italy14 Dr. Uyar, Yavuz Turkey15 Dr. Kota, Majlinda Albania16 Dr. Van Esbroeck, Marjan Belgium17 Vanhomwegen, Jessica Fellow18 Dr. Yagci Caglayik, Dilek Turkey
EpiSouthEpiSouth--PlusPlusEpiSouthEpiSouth PlusPlus
The Network for the Control of Public Health Threats and
other risks in the Mediterranean Region and Balkans
Handan KalaycıoğluRefik Saydam National Public Health Agency , Ankara, Turkey
on behalf of the EpiSouth Plus Partnerson behalf of the EpiSouth Plus Partners
1
2
EU Countries at the Project starting (Oct 2006)
EU Member States Partners in EpiSouth Plus
Iss, ItalyASLTO1, Italy
IP France
MoH, MaltaIPHB, RomaniaNIPH SloveniaIP, France
ISC III, SpainInVS, France
NCIPD B l i
NIPH, SloveniaPadua GH, Italy
INMI, ItalyCINECA It lNCIPD, Bulgaria
HCDCP, GreeceMoH, Cyprus
CINECA, ItalyIPH, Croatia
(to be verified)
3
12 th April 201112 th April 2011
Non EU Member States Partners in EpiSouth PlusNon-EU Member States Partners in EpiSouth Plus•ALBANIA, Tirana (Institute of Public
Health);• ALGERIA, Alger (National Institute of
Institute of Public Health);• LEBANON Beirut (Ministry of Public, g (
Public Health);• BOSNIA & HERZEGOVINA (Ministry of Civil
Affairs, Sarajevo; Ministry of Health andSocial Welfare, Banja Luka, Republic of
• LEBANON, Beirut (Ministry of PublicHealth);
• MONTENEGRO, Podgorica (Institute ofPublic Health);
• MOROCCO Rabat (Ministry of Health);, j , pSrpska; Public Health Institute, Mostar,
Federation of B&H);• CROATIA, Zagreb (Croatian National
Institute of Public Health);
• MOROCCO, Rabat (Ministry of Health);• PALESTINE, Ramallah (Ministry of Health);
• SERBIA, Belgrade (Institute of PublicHealth);
• SYRIA Damascus (Ministry of Health);)• EGYPT, Cairo (Ministry of Health and
Population);• FYROM–Former Yugoslav Republic ofMacedonia, Skopje (Institute for Health
• SYRIA, Damascus (Ministry of Health);• TUNISIA, Tunis (Ministry of Health);
• TURKEY, Ankara (Ministry of Health; RefikSaydam National Public Health Agency)
• LIBYA Tripoli (Infectious Diseasespj (Protection; Clinic of Infectious Diseases);• ISRAEL (Center for Disease Control, Tel
Hashomer; Ministry of Health,Jerusalem);
• LIBYA, Tripoli (Infectious DiseasesDepartment Tripoli Central Hospital)
4
• JORDAN, Amman (Ministry of Health);
5
Countries as per September 2010
EpiSouthEpiSouth--PlusPluspp
Starting date: 15 October 2010Starting date: 15 October 2010
Duration: 30 months
Co-Funding Agencies:EU DGSANCO EU DGDEVCO It li M H EU DGSANCO,EU DGDEVCO,Italian MoH,
ECDC
6
General ObjectiveGeneral Objectivejj
To increase the health security in the Mediterranean Area To increase the health security in the Mediterranean Area yyand Balkans by enhancing and strengthening the and Balkans by enhancing and strengthening the
preparedness to common health threats and other preparedness to common health threats and other risks risks at national and regional levels in the Countries of at national and regional levels in the Countries of
EpiSouth Network EpiSouth Network in the framework of the International in the framework of the International Health Regulations implementationHealth Regulations implementationHealth Regulations implementationHealth Regulations implementation..
7
Specific Objective (1)Specific Objective (1)
i) Establishment of a Mediterranean Regional L b t i t k (WP4)Laboratories network (WP4):
A network of regional laboratories will be established in order to facilitate common threats detection in theorder to facilitate common threats detection in the countries involved.
WP leaders: French Institute Pasteur & Refik Saydam National Public Health Agency, Ministry of Health of Turkey
8
g y, y f f y
S f O ( )S f O ( )Specific Objective (1)Specific Objective (1)Main needs and gaps to be addressedMain needs and gaps to be addressed
i) Establishment of a Mediterranean Regional Laboratories network (WP4):
Lack of cross-border lab facilities services for Med CountriesStrengthening complementary with the vertical and fragmented lab
t k tl ti i thnetworks presently operating in the areaOvercoming national logistic and legislation constraints
9
Specific Objective (2)Specific Objective (2)
ii) Promotion of common procedures in interoperable Generic Preparedness and Risk management for the Countries involved in the Network (WP5):in the Network (WP5):Specific capacity building measures will address the need of interoperability and intersectoral collaboration of countries' preparedness plans to fit the requirements of the IHR and to ensurepreparedness plans to fit the requirements of the IHR and to ensure multi-country harmonic and prompt response.
WP l d S i h I i d S l d C l III & h I i WP leaders: Spanish Instituto de Salud Carlos III & the Institut National de Santé Publique of Algeria.
10
Specific Objective (2)Specific Objective (2)Specific Objective (2)Specific Objective (2)
Main needs and gaps to be addressedMain needs and gaps to be addressed
ii) P ti f d i i t bl G i P d dii) Promotion of common procedures in interoperable Generic Preparedness and Risk management for the Countries involved in the Network (WP5):
Reducing the variability of procedures in the Countries involvedContributing to enhancing capacity and sharing field experiencesStrengthening cross-border concerted actions
GFacilitating national GPP development and communication strategy
11
Specific Objectives (3)Specific Objectives (3)
iii) Interoperable Early warning systems (EWS) and alerts platform able to ) p y g y ( ) pshare info between EpiSouth countries and with other Early Warning platforms and optimization of EI (WP6):
Participating countries should be able to share alerts generated by their national EWS p g g ywith the EpiSouth EWS platform and other EWSs, including the European Early Warning and Response System (EWRS), in the EPIS/ECDC environment.
Exchanging of national alerts with cross border potential and Epidemic Intelligence information that could be determinant to prevent health risk dissemination.
WP leaders: French Institut de Veille Sanitaire & MECIDS - Middle East Consortium for Infectious Diseases Surveillance -
12
S f O ( )S f O ( )Specific Objective (3)Specific Objective (3)Main needs and gaps to be addressedMain needs and gaps to be addressed
iii) Interoperable Early warning systems (EWS) and alerts' platform able toiii) Interoperable Early warning systems (EWS) and alerts platform able to share info between EpiSouth countries and with other Early Warning platforms and optimization of EI (WP6):
Enhancing “horizontal” cross-border and inter-countries alerts sharing in the Med AreaComplementing the presently operating EWSs (national > supraComplementing the presently operating EWSs (national > supra-national) with the info from the Med EWSOptimisation and minimization of duplication of EI activities
13
Specific Objectives (4)Specific Objectives (4)i ) P d ti f id li d t t i d t b d iv) Production of guidelines and strategic documents based onassessments and surveys aimed at facilitate IHR implementation(WP7):(WP7):In order to support the implementation of IHR, specific surveys
andassessments will be conducted among the EpiSouth Countries inorder to describe how national plans and legislations canpinteract/interfere with IHR requirements
14
Specific Objective (4)Main needs and gaps to be addressediv) Production of guidelines and strategic documents based onassessments and surveys aimed at facilitate IHR implementation(WP7):(WP7):� Define obstacles and constraints which are affectingcapacities’ assessment and adequacy in the countriesp q yinvolved� Contribute to the definition and implementation ofappropriate strategies which facilitate IHR national plansin accordance with the requirements
15
Wp4: Regional Mediterranean Laboratory Network
Co-leadership: RSNPHA, Turkey and Institut Pasteur, France
16
11stst SC Meeting SC Meeting –– Luxembourg Luxembourg -- 3 February 20113 February 2011
• General Objectives:
1. Setup a Regional Mediterranean Laboratory Network, with all countries of 1. Setup a Regional Mediterranean Laboratory Network, with all countries of the EpiSouth plus network, for an optimal surveillance of communicable diseases
S ifi Obj ti• Specific Objectives:
1. Create a complementary laboratory network to the already set up epidemiological network from EpiSouthepidemiological network from EpiSouth
2. Strengthen capacity of the different countries involved 3. Have the most adapted methods set up to the most relevant
questions/needs in the region. (common identified needs, involving at least q g ( , gone lab of each concerned country)
4. Optimisation exchange (information, samples) between the different partners and international organisations (WHO, ECDC, IEO, …)
5 Aim at sustainability
17
5. Aim at sustainability
St t t hi th l (1) • Strategy to achieve these goals (1):
Identification of priority areas of action (general needs, pathogens and corresponding diseases) Identification and meeting of expert committee to set minimum
i t d d requirements needed Identification of laboratories meeting the requirements and interested in contributing to the EpiSouth initiativet k li k ith th i ti t k to make link with the existing networks Mapping of existing biological expertise (Labs and Networks)Meeting with the heads of Laboratories interested in the approach Identification of strengths and needs of laboratories for diagnoses for priority diseases in the region: human, technical and organizational
18
• Strategy to achieve these goals (2):
Piloting of the Directory of Regional Laboratories on the websitePreliminary recommendations on training and capacity buildingOne week training module at PI Paris One week training module at PI Tunis (or RSNPHA Turkey) Stages at Pasteur or other Institutes (2 persons for 1 month each or more for g ( pshorter period of time)Draft a Recommendation DocumentFollow upFollow up
19
• Identification of priority areas of action (pathogens and corresponding diseases)
- Lab management and biosafety- Communicable diseaseCommunicable disease- Endemic in the region of interest :• High prevalence (TB)• Change of endemicity of the disease, spread (eg due to climate
change (Leishmaniasis), human migration)• Emerging character: pathogen (West Nile )• Emerging character: pathogen (West Nile, …)• Increased incidence in humans (resistance, …)
20
- Increase lab capacity may change effectiveness of surveillance (Vaccine preventable) ( p )
- A certain expertise should be present (sustainability)- Fall back on existing networks (TB, influenza, Leishmaniasis, ….)
Importance of displaced populations (human migration) (link with - Importance of displaced populations (human migration) (link with IHR, eg TB)
- According to need not yet addressed by others
Questionnaires will be sent to FP for priority setting of preselected diseases
21
Piloting of the Directory of Regional Laboratories on the website Follow up and network “animation” Follow up and network animation
- Regular contact with FP and heads of Labs - Create a strong link with the surveillance and early warning network- Make exchange of documents possible - Make exchange of documents possible - Promote standardisation for more homogeneous surveillance- Link with other existing initiatives
Make link with IHR activities- Make link with IHR activities- Make course material available- Quality control network
22
23